Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
作者信息
Winney R J, Bone J M, Anderson T J, Robson J S
出版信息
Calcif Tissue Res. 1977 May;22 Suppl:94-100. doi: 10.1007/BF02064047.
PMID:912593
Abstract
摘要
相似文献
1
Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Calcif Tissue Res. 1977 May;22 Suppl:94-100. doi: 10.1007/BF02064047.
2
1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Calcif Tissue Res. 1977 May;22 Suppl:105-11. doi: 10.1007/BF02064049.
3
Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
Kidney Int. 1979 Feb;15(2):196-204. doi: 10.1038/ki.1979.25.
4
1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
Calcif Tissue Res. 1977 May;22 Suppl:371-5. doi: 10.1007/BF02064103.
5
1,25-dihydroxycholecalciferol in patients with chronic renal failure.
Proc Eur Dial Transplant Assoc. 1973;10(0):202-9.
6
The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
Calcif Tissue Res. 1977 May;22 Suppl:112-6. doi: 10.1007/BF02064050.
7
1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
Isr J Med Sci. 1978 Jul;14(7):731-5.
8
The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.1α(OH)D3和1α,25(OH)2D3对肾性骨营养不良患者骨骼的影响。
Am J Med. 1978 Jan;64(1):101-7. doi: 10.1016/0002-9343(78)90184-5.
9
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.1,25-二羟维生素D3与24,25-二羟维生素D3在肾性骨营养不良长期治疗中的比较
Proc Eur Dial Transplant Assoc. 1980;17:543-7.
10
Renal osteodystrophy in dialysis patients: diagnosis and treatment.透析患者的肾性骨营养不良：诊断与治疗
Artif Organs. 1998 Jul;22(7):530-57. doi: 10.1046/j.1525-1594.1998.06198.x.
本文引用的文献
1
Control of secondary hyperparathyroidism during long-term hemodialysis.长期血液透析期间继发性甲状旁腺功能亢进的控制
Am J Med. 1971 May;50(5):692-9. doi: 10.1016/0002-9343(71)90125-2.
2
Total body calcium and long-term calcium balance in chronic renal disease.
J Lab Clin Med. 1973 Aug;82(2):226-40.
3
Azotaemic renal osteodystrophy: a quantitative study on iliac bone.氮质血症性肾性骨营养不良：髂骨的定量研究。
J Clin Pathol. 1973 Feb;26(2):83-101. doi: 10.1136/jcp.26.2.83.
4
1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure.1-α-羟基胆钙化醇替代肾脏激素1,25-二羟基胆钙化醇用于慢性肾衰竭
Lancet. 1973 Sep 29;2(7831):696-9. doi: 10.1016/s0140-6736(73)92536-1.
5
1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
Proc Eur Dial Transplant Assoc. 1976;12:227-36.
6
Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis.重复透析期间透析液钙浓度和维生素D对血清甲状旁腺激素的影响。
Kidney Int. 1975 Jun;7(6):422-32. doi: 10.1038/ki.1975.60.
7
The kidney as an endocrine organ involved in the function of vitamin D.肾脏作为一个参与维生素D功能的内分泌器官。
Am J Med. 1975 Jan;58(1):39-47. doi: 10.1016/0002-9343(75)90531-8.
8
Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Lancet. 1976 May 22;1(7969):1092-5. doi: 10.1016/s0140-6736(76)90061-1.
9
Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.
Lancet. 1976 May 15;1(7968):1044-7. doi: 10.1016/s0140-6736(76)92220-0.
Zotero 插件